-DOCSTART- -X- O
Respiratory -X- _ B-Patient
RNA -X- _ I-Patient
viruses -X- _ I-Patient
are -X- _ O
constantly -X- _ O
evolving -X- _ O
, -X- _ O
thus -X- _ O
requiring -X- _ O
development -X- _ O
of -X- _ O
additional -X- _ O
prophylactic -X- _ O
and -X- _ O
therapeutic -X- _ O
strategies. -X- _ O
Harnessing -X- _ O
the -X- _ O
innate -X- _ O
immune -X- _ O
system -X- _ O
to -X- _ O
non-specifically -X- _ O
respond -X- _ O
to -X- _ O
viral -X- _ O
infection -X- _ O
has -X- _ O
the -X- _ O
advantage -X- _ O
of -X- _ O
being -X- _ O
able -X- _ O
to -X- _ O
circumvent -X- _ O
viral -X- _ O
mutations -X- _ O
that -X- _ O
render -X- _ O
the -X- _ O
virus -X- _ O
resistant -X- _ O
to -X- _ O
a -X- _ O
particular -X- _ O
therapeutic -X- _ O
agent. -X- _ O
Viruses -X- _ O
are -X- _ O
recognized -X- _ O
by -X- _ O
various -X- _ O
cellular -X- _ O
receptors -X- _ O
, -X- _ O
including -X- _ O
Toll-like -X- _ O
receptor -X- _ O
( -X- _ O
TLR -X- _ O
) -X- _ O
3 -X- _ O
which -X- _ O
recognizes -X- _ O
double-stranded -X- _ O
( -X- _ O
ds -X- _ O
) -X- _ O
RNA -X- _ O
produced -X- _ O
during -X- _ O
the -X- _ O
viral -X- _ O
replication -X- _ O
cycle. -X- _ O
TLR3 -X- _ B-Intervention
agonists -X- _ I-Intervention
include -X- _ O
synthetic -X- _ B-Intervention
dsRNA -X- _ I-Intervention
such -X- _ I-Intervention
as -X- _ I-Intervention
poly -X- _ I-Intervention
( -X- _ I-Intervention
IC -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
poly -X- _ I-Intervention
( -X- _ I-Intervention
ICLC -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
poly -X- _ I-Intervention
( -X- _ I-Intervention
AU -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
These -X- _ O
agents -X- _ O
have -X- _ O
been -X- _ O
evaluated -X- _ O
and -X- _ O
found -X- _ B-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
effective -X- _ I-Outcome
against -X- _ I-Outcome
a -X- _ I-Outcome
number -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
agents. -X- _ I-Outcome
One -X- _ O
major -X- _ O
limitation -X- _ O
has -X- _ O
been -X- _ O
the -X- _ O
toxicity -X- _ O
associated -X- _ O
with -X- _ O
administration -X- _ O
of -X- _ O
these -X- _ O
drugs. -X- _ O
Significant -X- _ O
time -X- _ O
and -X- _ O
effort -X- _ O
have -X- _ O
been -X- _ O
spent -X- _ O
to -X- _ O
develop -X- _ O
alternatives -X- _ O
/ -X- _ O
modifications -X- _ O
that -X- _ O
will -X- _ O
minimize -X- _ O
these -X- _ O
adverse -X- _ O
effects. -X- _ O
This -X- _ O
review -X- _ O
will -X- _ O
focus -X- _ O
on -X- _ O
the -X- _ O
TLR3 -X- _ B-Patient
agonist -X- _ I-Patient
, -X- _ I-Patient
poly -X- _ I-Patient
( -X- _ I-Patient
IC -X- _ I-Patient
) -X- _ I-Patient
/ -X- _ I-Patient
( -X- _ I-Patient
ICLC -X- _ I-Patient
) -X- _ I-Patient
with -X- _ O
respect -X- _ O
to -X- _ O
its -X- _ O
use -X- _ O
in -X- _ O
treatment -X- _ O
/ -X- _ O
prevention -X- _ O
of -X- _ O
respiratory -X- _ B-Patient
viral -X- _ I-Patient
infections -X- _ I-Patient
. -X- _ O

